Please ensure Javascript is enabled for purposes of website accessibility

Why Bellicum Pharmaceuticals Stock Is Crashing Today

By George Budwell - Jan 31, 2018 at 11:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A major clinical setback is wrecking havoc on Bellicum's share price today.

What happened

Shares of the clinical-stage cell therapy company Bellicum Pharmaceuticals (BLCM -8.82%) are in free fall on Wednesday.

The biotech announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its lead product candidate BPX-501 that's being assessed as an adjunct T-cell therapy administered after haploidentical hematopoietic stem cell transplant. The hold reportedly stems from three cases of potentially treatment-related encephalopathy (abnormal brain function) that occurred during an ongoing trial. Bellicum's shares are down by 33.5% at 10:11 a.m EST on heavy volume in response to this news.

A chalkboard chart illustrating a downward trajectory.

Image source: Getty Images.

So what

This clinical setback may be the beginning of the end for Bellicum. The company has staked the bulk of its value proposition on producing a safer adoptive cell therapy than the current industry leaders. So, a serious safety issue like encephalopathy -- if shown to be treatment-related -- would be a big blow to Bellicum's claim of developing a "best-in-class" adoptive cell therapy.

Now what

Per its press release after the Tuesday's closing bell, Bellicum noted that this FDA clinical hold did not impact BPX-501's ongoing pivotal trial in Europe. However, this silver lining, if you will, may not matter all that much to current shareholders due to the company's deteriorating financial position.

Bellicum was almost certainly going to tap the public markets in a big way to shore up its balance sheet soon. As the company is now probably going to have to execute a sizable secondary offering at a significantly lower share price, the dilutive impact on shareholders will be even greater. As such, this speculative biotech stock is best avoided until the inevitable capital raise occurs, and this clinical hold is favorably resolved.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bellicum Pharmaceuticals, Inc. Stock Quote
Bellicum Pharmaceuticals, Inc.
$1.55 (-8.82%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.